Introduction
============

Genetic diversity is observed among populations of different ancestries. Allele frequencies can exhibit large diversity among populations due to forces such as genetic drift and natural selection. Although most common variants are shared worldwide, rare variants (minor allele frequency \[MAF\] \<1%) have the tendency to cluster in specific populations. Population-specific rare variants tend to have a strong functional effect \[[@r1]\].

In age-related macular degeneration (AMD), large variability in rare variant frequency has been reported in case-control studies of various populations; for instance, for variant [rs121913059](https://www.ncbi.nlm.nih.gov/snp/?term=rs121913059) (p.Arg1210Cys) in complement factor H (*CFH*; HGNC 4883, OMIM [134370](https://www.ncbi.nlm.nih.gov/omim/?term=134370)). *CFH* [rs121913059](https://www.ncbi.nlm.nih.gov/snp/?term=rs121913059) was first reported in a case-control study from the United States \[[@r2]\]. Several studies replicated the finding \[[@r3]-[@r5]\], but other Caucasian studies \[[@r6]-[@r9]\] and Asian studies \[[@r10],[@r11]\] were unable to replicate the strong association ([Table 1](#t1){ref-type="table"}). Another example, variant [rs141853578](https://www.ncbi.nlm.nih.gov/snp/?term=rs141853578) (p.Gly119Arg) in complement factor I (*CFI*; HGNC 5394, OMIM [217030](https://www.ncbi.nlm.nih.gov/omim/?term=217030)) first reported in a European cohort \[[@r7]\], was screened in a British \[[@r12]\] and American \[[@r13]\] cohort (odds ratio \[OR\] = 22.2; 8.5 and 2.6, respectively). However, although the variant was associated with AMD, the risk effect size was much weaker when compared to the first report.

###### Minor allele frequencies of the *CFH* [rs121913059](https://www.ncbi.nlm.nih.gov/snp/?term=rs121913059) (p.Arg1210Cys) variant among different geographical regions reported in literature.

  **Descent**                               **Previous reports**              **Carriers (n)**   **Total Cases (n)**   **Total Controls (n)**   **MAF Cases (%)‡**   **MAF  Controls (%)‡**   **Odds-Ratio**   **P-value**
  ----------------------------------------- --------------------------------- ------------------ --------------------- ------------------------ -------------------- ------------------------ ---------------- --------------
  *Various populations, European descent*   Fritsche 2016 \[[@r3]\]           108                16,144                17,832                   0.319                0.014                    20.3             8.9×10^−24^
  Eastern USA                               Raychaudhuri 2011 \[[@r2]\]^\#^   34                 2414                  1120                     0.684                0.045                    NA               8.0 × 10^−5^
  Zhan 2013 \[[@r5]\]                       24                                2268               2268                  0.507                    0.022                23.1                     2.9 × 10^−6^     
  European                                  Helgason 2013 \[[@r8]\]           0                  1143                  51,435                   0.000                0.000                    NA               NA
  Saksens 2016 \[[@r9]\]\*                  0                                 1589               1386                  0.000                    0.000                NA                       NA               
  Recalde 2016 \[[@r4]\]                    5                                 259                330                   0.965                    0.000                NA                       NA               
  Asian                                     Shen 2012 \[[@r11]\]              0                  258                   426                      0.000                0.000                    NA               NA
  Miyake 2015 \[[@r10]\]                    1                                 1364               1208                  0.037                    0.000                NA                       NA               

Additional publications from: the Boston study^\#^ \[[@r13],[@r15]\] and EUGENDA study\* \[[@r6],[@r7]\]. ‡ major allele C, minor allele T. NA=Not available or not reported.

In a recent genome-wide association study conducted by the International Age-related Macular Degeneration Genomics Consortium (IAMDGC) \[[@r3]\], seven rare variants were observed to independently confer risk for AMD. All seven rare variants are localized in or near genes encoding components of the complement system, namely, *CFH, CFI*, and complement components 3 and 9 (*C3*, HGNC 1318, OMIM [120700](https://www.ncbi.nlm.nih.gov/omim/?term=120700) and *C9*, HGNC: 1358 , OMIM [120940](https://www.ncbi.nlm.nih.gov/omim/?term=120940)).

The difference in association for rare variants among different AMD case-control studies may reflect the difference in distribution of such rare alleles across geographic regions. This observation raises the question whether these variants identified by the IAMDGC are represented in all case-control studies or whether the association is driven by one or more studies from a specific geographic region. Therefore, we sought to evaluate the representation of these seven AMD-associated rare variants in 24 AMD case-control studies of different geographic regions.

Methods
=======

Data for this study were provided by the IAMDGC. The genotypes are in part available via dbGaP under accession number phs001039.v1.p1. The original data set contained data from 40,633 individuals of European ancestry as described by Fritsche et al. \[[@r3]\].

For analyses of the current study, participants from the Utah case-control study were excluded due to their mixed regions of origin. In addition, the Jerusalem case-control study was excluded due to its small sample size compared to the other geographic regions. Final analyses were performed on 39,582 participants derived from 24 of 26 studies \[[@r3]\]. The included studies were grouped in five geographic regions: eastern USA, western Europe, Britain, western USA, and Australia (Table S1). Data were collected by all study groups in accordance with the tenets of the Declaration of Helsinki; participants provided informed consent, and study protocols were approved by local ethical committees \[[@r3]\]. Ancestry was determined based on the first two principal components using autosomal genotyped variants together with genotype information of the samples from the Human Genome Diversity Project \[[@r3]\]. The final data set included 39,582 successfully genotyped subjects, including 15,527 advanced AMD cases, 6,537 non-advanced AMD cases, and 17,518 control individuals of European ancestry.

The MAF in each region was calculated and compared independently of AMD status. For comparison of effect sizes and interaction analyses, individuals were assigned "AMD" when they exhibited signs of (1) advanced AMD defined as geographic atrophy and/or choroidal neovascularization in at least one eye, or (2) non-advanced AMD defined as pigmentary changes in the macula and/or more than five macular drusen with a diameter more than 63 μm. Individuals without any reported signs of AMD were assigned "No AMD."

Genotype data of seven rare genetic variants were selected from array-based data generated by the IAMDGC \[[@r3]\]. Fritsche et al. \[[@r3]\] showed these seven rare variants were independently associated with AMD: *CFH* [rs121913059](https://www.ncbi.nlm.nih.gov/snp/?term=rs121913059) (p.Arg1210Cys), *CFI* [rs141853578](https://www.ncbi.nlm.nih.gov/snp/?term=rs141853578) (p.Gly119Arg), *C3* [rs147859257](https://www.ncbi.nlm.nih.gov/snp/?term=rs147859257) (p.Lys155Gln), and *C9* [rs34882957](https://www.ncbi.nlm.nih.gov/snp/?term=rs34882957) (p.Pro167Ser) and three non-coding variants in or near *CFH* ([rs148553336](https://www.ncbi.nlm.nih.gov/snp/?term=rs148553336), [rs35292876](https://www.ncbi.nlm.nih.gov/snp/?term=rs35292876), and [rs191281603](https://www.ncbi.nlm.nih.gov/snp/?term=rs191281603)).

The software package SAS (Statistical Analysis System Institute, SAS Institute Inc., Cary, NC, V9.2) was used to compare MAFs between the different geographic regions in a logistic regression analysis with the Firth correction (S1 Supporting information) \[[@r14]\]. Furthermore, we estimated the mean allele frequency of each rare genetic variant in each of the geographic regions including a 95% confidence interval (details provided in S1 Supporting information). To study the potential difference in the effect size of each variant between the geographic regions, interaction analyses were performed using binary logistic regression models with SPSS statistics software (IBM SPSS Statistics, IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY, V22.0).

Results
=======

Demographic characteristics for each of the five geographic regions are shown in Supporting Information Table S1. The characteristics of the participants from the different regions were comparable, although the British study samples were slightly younger than the others, and the western European study samples included relatively more female participants compared to the remainder. These differences were comparable in the cases and the controls.

We analyzed the difference in distribution of the seven rare variants among case-control studies from eastern USA, western Europe, Britain, western USA, and Australia using logistic regression analysis with the Firth correction ([Table 2](#t2){ref-type="table"}; [Figure 1](#f1){ref-type="fig"}) and observed a difference in the distribution of the variants *CFH* [rs121913059](https://www.ncbi.nlm.nih.gov/snp/?term=rs121913059) (p.Arg1210Cys, p=0.004) and *CFH* [rs35292876](https://www.ncbi.nlm.nih.gov/snp/?term=rs35292876) (p=0.001) across the different geographic regions. *CFH* [rs121913059](https://www.ncbi.nlm.nih.gov/snp/?term=rs121913059) was found at a higher frequency in eastern USA, especially compared to Britain and Australia (p=0.011 and p=0.003, respectively). *CFH* [rs35292876](https://www.ncbi.nlm.nih.gov/snp/?term=rs35292876) was found at a higher frequency in western Europe, compared to all other regions (ranging from p\<0.001 in Britain to p=0.012 in eastern USA). The distribution of variants *CFH* [rs121913059](https://www.ncbi.nlm.nih.gov/snp/?term=rs121913059) (p.Arg1210Cys) and *CFH* [rs35292876](https://www.ncbi.nlm.nih.gov/snp/?term=rs35292876) was not confounded by the distribution of individuals with advanced and non-advanced AMD across the geographic regions (Table S2). The other five variants were found to have similar allele frequencies among all geographic regions.

###### Distribution and interaction analysis of seven rare AMD-associated genetic variants across five geographical regions.

  **Gene**                           **Difference in distribution between geographical regions^\#^**   **Interaction Analysis\***   **Overall effect size‡**
  ---------------------------------- ----------------------------------------------------------------- ---------------------------- --------------------------
  *CFH* rs121913059 (p.Arg1210Cys)   **0.004**                                                         0.665                        24.2 (8.9--65.6)
  *CFI* rs141853578 (p.Gly119Arg)    0.707                                                             0.563                        3.7 (2.5--5.7)
  *C3* rs147859257 (p.Lys155Gln)     0.665                                                             0.680                        2.8 (2.3--3.4)
  *C9* rs34882957 (p.Pro167Ser)      0.315                                                             0.572                        1.7 (1.5--2.0)
  *CFH* rs148553336                  0.053                                                             0.015                        0.5 (0.4--0.6)
  *CFH* rs35292876                   **0.001**                                                         0.709                        2.3 (2.0--2.6)
  *CFH* rs191281603                  0.735                                                             0.980                        0.9 (0.7--1.1)

^\#^Logistic Regression with Firth correction. Individual Wald Chi-Square from likelihood ratio test for each of the variants across the geographical regions. \*Interaction Analysis: Effect sizes in entire study and interaction analysis to study potential differences in effect size between cohorts. ‡Overall effect size adjusted for geographical region. Bold values: p value considered significant after Bonferroni correction (p\<0.007).
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The difference in distribution is also reflected by the estimated MAFs of each variant in the different geographic regions (Table S3). The allele frequency of *CFH* [rs121913059](https://www.ncbi.nlm.nih.gov/snp/?term=rs121913059) is nearly three times higher in eastern USA than in Britain and Australia. Noteworthy is the near absence of this risk variant in control individuals without AMD, indicating that the difference in distribution appears to be driven solely by individuals with AMD (Table S4).

To determine whether the effect size was influenced by geographic region, we performed interaction analyses for each variant. We observed that the risk associated with each specific rare variant is independent of the geographic region ([Table 2](#t2){ref-type="table"}). The overall effect sizes of the rare variants are comparable to the effect sizes reported in the IAMDGC study \[[@r3]\].

Discussion
==========

The distribution of rare *CFH* variants [rs121913059](https://www.ncbi.nlm.nih.gov/snp/?term=rs121913059) (p.Arg1210Cys) and [rs35292876](https://www.ncbi.nlm.nih.gov/snp/?term=rs35292876) was significantly different between several of the studied geographic regions. This result confirms differences reported in previous studies for the *CFH* [rs121913059](https://www.ncbi.nlm.nih.gov/snp/?term=rs121913059) variant \[[@r2]-[@r11],[@r13],[@r15]\] ([Table 1](#t1){ref-type="table"}). *CFH* [rs121913059](https://www.ncbi.nlm.nih.gov/snp/?term=rs121913059) was first associated with AMD in a study from the USA \[[@r2]\]; however, the association was not consistently replicated in Dutch/German \[[@r7]\], Icelandic \[[@r8]\], Japanese \[[@r10]\], and Chinese \[[@r11]\] studies. In this study, we confirmed the hypothesis that rare variants can be differently distributed among geographic regions, but as expected, the risk estimates are comparable across the geographic regions. Rare variants tend to be recent, and therefore, their distribution tends to be restricted to a specific region. Interpretation of rare variants, therefore, may be focused to a geographic region or population \[[@r16],[@r17]\].

In AMD, a difference in geographic distribution has already been described for common risk haplotypes of the *CFH* and *ARMS2* (HGNC: 32685, OMIM [611313](https://www.ncbi.nlm.nih.gov/omim/?term=611313)) genes, which are the most prominent common genetic AMD risk factors \[[@r3]\]. Although Asian populations report a lower frequency of *CFH* risk haplotypes, the opposite holds true for the *ARMS2/HTRA1* risk haplotype which is more prevalent in Asians compared to Caucasian populations \[[@r18],[@r19]\]. These patient- and population-specific variations have implications for genetic counseling and carrier screening in diagnostic and research settings.

In addition to single variant associations, a significant burden of rare variants in the *CFH* and *CFI* genes has been reported for AMD \[[@r3],[@r15]\]. The disease burden in these genes is attributed to the cumulative effect of rare coding variants, some of which are identified in multiple studies, while others are restricted to a single population or even a single patient \[[@r20]\]. Carriers of specific rare genetic variants in the complement genes that increase complement activation may benefit more from complement-inhibiting therapy than those who do not carry such variants \[[@r20]\]. Personalized treatment aiming at complement-activating rare variants in clinical trials may be applicable only to specific populations where these variants are sufficiently common.

It is likely that additional rare variants, other than *CFH* Arg1210Cys and [rs35292876](https://www.ncbi.nlm.nih.gov/snp/?term=rs35292876), fluctuate in frequency among geographic regions. To identify these variants, additional large sequencing studies will need to be performed in populations originating from diverse geographic regions. Until now, large sequencing initiatives are predominantly of North American or European origin, and sample sizes for non-European-descent population are limited \[[@r3],[@r21]\]. Recruiting case-control studies from other geographic regions and ancestries could allow for identification of novel highly penetrant rare variants implicated in AMD pathogenesis. These variants may be located in known AMD pathways, such as the complement system, or novel pathways \[[@r22]\]. For example, Asian populations have a different genetic predisposition for AMD than Europeans. Only half of the common European loci could be replicated in East Asians \[[@r23]\]. Furthermore, the rare variants *CFH* rs121913059 (p.Arg1210Cys), *CFI* rs141853578 (p.Gly119Arg), and *C3* rs147859257 (p.Lys155Gln) were not identified in Asian populations according to public database gnomAD \[[@r24]\]. It has been postulated that rare variants in Asian populations may be found in other genes, for example, involved in cholesterol and lipid metabolism \[[@r25]\].

In conclusion, we demonstrated that rare AMD-associated variants *CFH* rs121913059 and rs35292876 are differently distributed among different geographic regions. These results emphasize the importance of identifying population-specific rare variants in AMD.
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